RxDoctor Payments Data

Barry Fuller, MD

Ophthalmology · Ypsilanti, MINPI 1134182645

Payments from drug & device makers

$2,046in general payments, 2019–2025

Across 87 payments — averaging $23.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tarsus Pharmaceuticals, Inc.$322
  • AbbVie$230
  • Sun Pharmaceutical Industries Inc.$187
  • Rxsight Inc$180
  • Bausch & Lomb Americas Inc.$106
  • Amgen$99
  • plus $923 from 22 others

What the payments were for

  • Food & beverage$2,046100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,046 in reported general payments places this provider in the 60th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$233,017
Medicare patients
831
Services billed
2,143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost67$32,912
Travoprost25$8,132
Latanoprost312$6,947
CombiganBrimonidine Tartrate/Timolol13$5,478
Prednisolone Acetate92$4,794
Brimonidine Tartrate34$3,088
Tobramycin-DexamethasoneTobramycin/Dexamethasone52$2,422
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$2,285
ErythromycinErythromycin Base161$2,105
Timolol Maleate70$1,327
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha92$1,203
Ketorolac Tromethamine66$1,137
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat24$548
Diclofenac Sodium14$133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$230$38,39080 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Ypsilanti

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →